ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Are 'low T' and 'hypoactive sexual desire disorder' a tale of profit trumping science?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 44888" data-attributes="member: 3"><p>or men, it is "Low T" -- declining testosterone levels often accompanied by low libido, a natural element of aging. Thanks to a <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569444/" target="_blank">2006 study funded by a company that sold testosterone products</a>, suddenly 38% of men over 45 -- some 14 million Americans -- were deemed to have it.</p><p>For women, it is hypoactive sexual desire disorder -- recently renamed female sexual interest/arousal disorder -- which critics say is a questionable medical diagnosis.</p><p></p><p></p><p>In 1999, <a href="http://ttp://www.ncbi.nlm.nih.gov/pubmed/10022110" target="_blank">a paper written by authors with drug industry financial ties</a> found that 43% of women had some form of sexual dysfunction, including a lack of interest in sex.</p><p>Other drug industry-funded studies in the mid-2000s claimed some 9 million women had sexual dysfunction and were troubled by it.</p><p></p><p>Consider hypoactive sexual desire disorder and the drug flibanserin (Addyi).</p><p>After twice rejecting the drug, the FDA <a href="http://www.medpagetoday.com/publichealthpolicy/fdageneral/53129" target="_blank">approved it last year</a> over serious concerns about its safety raised by the agency's own doctors. The FDA researchers said the drug could cause a dramatic drop in blood pressure when taken with alcohol. That, in turn, could lead to women passing out.</p><p></p><p></p><p></p><p>The Addyi story has a familiar ring -- and it's not cha-ching. The financial success of Addyi is limited -- $100 million a year in sales at the most -- said Ram Selvaraju, a healthcare stock analyst and managing director with Rodman & Renshaw Research in New York.</p><p>He cited its poor effectiveness, $800 a month cost, and the fact alcohol should not be used with it.</p><p>"You want to have a glass of wine with your husband?" he said. "You can't do that."</p><p></p><p></p><p><a href="http://www.medpagetoday.com/special-reports/LoweringtheBar/58903" target="_blank">http://www.medpagetoday.com/special-reports/LoweringtheBar/58903</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 44888, member: 3"] or men, it is "Low T" -- declining testosterone levels often accompanied by low libido, a natural element of aging. Thanks to a [URL="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569444/"]2006 study funded by a company that sold testosterone products[/URL], suddenly 38% of men over 45 -- some 14 million Americans -- were deemed to have it. For women, it is hypoactive sexual desire disorder -- recently renamed female sexual interest/arousal disorder -- which critics say is a questionable medical diagnosis. In 1999, [URL="ttp://www.ncbi.nlm.nih.gov/pubmed/10022110"]a paper written by authors with drug industry financial ties[/URL] found that 43% of women had some form of sexual dysfunction, including a lack of interest in sex. Other drug industry-funded studies in the mid-2000s claimed some 9 million women had sexual dysfunction and were troubled by it. Consider hypoactive sexual desire disorder and the drug flibanserin (Addyi). After twice rejecting the drug, the FDA [URL="http://www.medpagetoday.com/publichealthpolicy/fdageneral/53129"]approved it last year[/URL] over serious concerns about its safety raised by the agency's own doctors. The FDA researchers said the drug could cause a dramatic drop in blood pressure when taken with alcohol. That, in turn, could lead to women passing out. The Addyi story has a familiar ring -- and it's not cha-ching. The financial success of Addyi is limited -- $100 million a year in sales at the most -- said Ram Selvaraju, a healthcare stock analyst and managing director with Rodman & Renshaw Research in New York. He cited its poor effectiveness, $800 a month cost, and the fact alcohol should not be used with it. "You want to have a glass of wine with your husband?" he said. "You can't do that." [URL]http://www.medpagetoday.com/special-reports/LoweringtheBar/58903[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Are 'low T' and 'hypoactive sexual desire disorder' a tale of profit trumping science?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top